Compare Amphastar Pharmaceuticals Inc (AMPH) vs DuPont de Nemours Inc (DD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs DuPont de Nemours Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.63 (market cap $826.08M), while DuPont de Nemours Inc trades at $132.26 (market cap $18.18B). The key difference: DuPont de Nemours Inc is far larger — about 22× Amphastar Pharmaceuticals Inc's market cap, and DuPont de Nemours Inc pays a 1.78% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | DD | |
|---|---|---|
Market Cap | $826.08M | $18.18B |
Sector | Health | Basic Materials |
52-Week High | $30.81 | $154.59 |
52-Week Low | $16.87 | $87.72 |
Enterprise Value | $1.22B | $20.65B |
Dividend Yield | — | 1.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
DuPont (DD) trades at $134.68, down 0.08% on the day, with a bearish technical signal and negative net income margin of -0.42% for 2025. Recent earnings have consistently beaten estimates, but revenue declined to $6.85B in 2025 from $12.4B in 2024. The company faces a lawsuit over 'forever chemicals' and completed a 3:1 reverse stock split in June 2026, while maintaining dividend payments.
The stock presents a mixed outlook: strong analyst consensus with a $227.20 price target suggests significant upside, but persistent profitability challenges and legal risks weigh on fundamentals. Investment opportunity hinges on earnings turnaround and resolution of regulatory pressures, though current technical weakness and cash flow trends indicate near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →
